Clinical Trial Update: A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial updating the design of a study comparing subcutaneous tislelizumab versus intravenous tislelizumab plus chemotherapy in unresectable or metastatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeOne Medicines | Conditions: Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: RECRUITING